Ningbo Menovo Pharmaceutical's subsidiary, the raw material of Atorvastatin calcium, passed the CDE technology evaluation.

Ningbo Menovo Pharmaceutical (603538.SH) has announced that its subsidiary, Xuan Cheng Ningbo Menovo Pharmaceutical Co., Ltd. (referred to as "Xuan Cheng Ningbo Menovo Pharmaceutical"), has recently received the approval and issuance of the "Chemical Raw Material Drug Marketing Application Approval Notice" for the raw material drug Atorvastatin Calcium from the National Medical Products Administration. The Atorvastatin Calcium raw material drug of Xuan Cheng Ningbo Menovo Pharmaceutical has passed the CDE technical review, demonstrating that the raw material drug meets the technical standards for drug evaluation in the country and can be sold in the domestic market. This will further enrich the product line of the subsidiary, contribute to expanding the company's business scope, facilitate the expansion of the company's integrated production range of raw material drugs, and enhance the advantage of the company's integrated production.